AJ13-- Pharmarcokinetics for Experimental Rheumatoid Arthritis treatment - SOURCES SOUGHT NOTICE Department of Veterans Affairs Network Contracting Office ( NCO) 05 Title: A Joint Targeted Drug Delivery Approach for Arthritis Therapy Toxicity and Pharmacokinetics 1. Purpose This Sources Sought Notice is issued solely for
AI helper
Market research for preclinical toxicology and pharmacokinetic studies on an experimental rheumatoid arthritis treatment. Requires GLP compliant toxicity testing and GLP or non-GLP pharmacokinetic studies in adult rats. Services include single dose intravenous toxicity testing, blood testing for organ damage markers, euthanasia, necropsy, histopathology, administration of single IV doses, blood sample collection, plasma processing, chemical extraction, LC-MS/MS quantification of dexamethasone and metabolite, and generation of PK parameters. A comprehensive written report is required. Period of performance is 1 year (September 15, 2026 - September 14, 2027). Interested vendors must submit capability statements including company details, UEI, SAM. gov registration, business size, socio-economic status, and demonstrated technical capability in GLP toxicology, rodent PK studies, LC-MS/MS analysis, histopathology, necropsy, and relevant past performance. Responses are due by July 29, 2026, **** EST.
Responses are requested no later than July 29, 2026, **** Eastern Standard Time. Please submit all capability statements directly to the contracting officer for review no later than nlt july 29, 2026 **** eastern standard time.
Vendors must demonstrate technical capability and experience performing GLP toxicology studies, rodent PK studies, LC-MS/MS analysis, histopathology, necropsy, and relevant past performance for biomedical R&D or FDA preclinical support. Demonstrated technical capability and experience performing: glp toxicology studies rodent pk studies lc ms ms analysis histopathology and necropsy relevant past performance for biomedical r d or fda preclinical support.